Pluripotent stem cells reveal the developmental biology of human megakaryocytes and provide a source of platelets for clinical application.

Access this Article

Search this Article

Abstract

Human pluripotent stem cells [PSCs; including human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs)] can infinitely proliferate in vitro and are easily accessible for gene manipulation. Megakaryocytes (MKs) and platelets can be created from human ESCs and iPSCs in vitro and represent a potential source of blood cells for transfusion and a promising tool for studying the human thrombopoiesis. Moreover, disease-specific iPSCs are a powerful tool for elucidating the pathogenesis of hematological diseases and for drug screening. In that context, we and other groups have developed in vitro MK and platelet differentiation systems from human pluripotent stem cells (PSCs). Combining this co-culture system with a drug-inducible gene expression system enabled us to clarify the novel role played by c-MYC during human thrombopoiesis. In the next decade, technical advances (e.g., high-throughput genomic sequencing) will likely enable the identification of numerous gene mutations associated with abnormal thrombopoiesis. Combined with such technology, an in vitro system for differentiating human PSCs into MKs and platelets could provide a novel platform for studying human gene function associated with thrombopoiesis.

Journal

  • Cellular and molecular life sciences : CMLS

    Cellular and molecular life sciences : CMLS 69(20), 3419-3428, 2012-10

    SP Birkhäuser Verlag Basel

Codes

  • NII Article ID (NAID)
    120004920418
  • NII NACSIS-CAT ID (NCID)
    AA11112963
  • Text Lang
    ENG
  • Article Type
    journal article
  • ISSN
    1420-682X
  • Data Source
    IR 
Page Top